CD30-Positive Lymphoproliferative Disorders.
Borderline lesions
CD30+ lymphoproliferative disorder
Cutaneous T-cell lymphoma
Extensive limb disease
Lymphomatoid papulosis
Primary cutaneous anaplastic large cell lymphoma
Therapeutic targets
Journal
Cancer treatment and research
ISSN: 0927-3042
Titre abrégé: Cancer Treat Res
Pays: United States
ID NLM: 8008541
Informations de publication
Date de publication:
Historique:
entrez:
1
1
2019
pubmed:
1
1
2019
medline:
2
7
2019
Statut:
ppublish
Résumé
Primary cutaneous CD30-positive lymphoproliferative disorders (CD30+ LPD) encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions [1]. CD30+ LPD are the second most common cutaneous T-cell lymphomas (CTCL) after mycosis fungoides (MF) and represent approximately 25% of all CTCL cases [2]. Their common phenotypic hallmark is an expression of the CD30 antigen, a cytokine receptor belonging to the tumor necrosis factor (TNF) receptor superfamily. Both LyP and pcALCL show numerous clinical, histological and immunophenotypic variants, and generally have an indolent course with a favorable prognosis. Overlapping features of LyP and pcALCL with other CD30+ T-cell lymphomas, inflammatory, and/or infectious conditions emphasize the importance of careful clinicopathologic correlation and staging.
Identifiants
pubmed: 30596222
doi: 10.1007/978-3-319-99716-2_12
doi:
Substances chimiques
Ki-1 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM